Dendritic Cell Vaccines for Lung Cancer
Author Information
Author(s): Perroud Maurício W Jr, Honma Helen N, Barbeiro Aristóteles S, Gilli Simone CO, Almeida Maria T, Vassallo José, Saad Sara TO, Zambon Lair
Primary Institution: State University of Campinas, Campinas, Brazil
Hypothesis
The study aims to evaluate the feasibility, safety, and immunologic responses of mature, antigen-pulsed autologous dendritic cell vaccines in patients with advanced non-small cell lung cancer.
Conclusion
The results suggest that the dendritic cell vaccine is safe and may improve immune responses, warranting further investigation in larger trials.
Supporting Evidence
- The vaccine was well tolerated with no severe adverse events reported.
- Two patients had a survival almost twice greater than the expected average.
- The lymphoproliferation assay showed an improvement in immune response after vaccination.
Takeaway
This study tested a new vaccine made from patients' own immune cells to help fight lung cancer, and it seemed safe and might help the immune system.
Methodology
Five patients with advanced NSCLC received two doses of dendritic cell vaccines, and their immune responses were measured using lymphoproliferation assays.
Potential Biases
The nonrandomized design may introduce bias in assessing the treatment effects.
Limitations
The small sample size limits the ability to draw definitive conclusions about the vaccine's efficacy.
Participant Demographics
The median age of participants was 60 years, with 3 males and 2 females.
Statistical Information
P-Value
0.005
Statistical Significance
p = 0.005
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website